Biotech Développement Conseils
Consulting firm (founded 2002) offering corporate strategy and business development advisory for life sciences organizations. Services include asset evaluation, commercial and partnership strategy, fundraising support, due diligence and IP/legal advisory. Operates internationally with a presence in Europe, Israel and the USA and has advised over 200 companies.
Industries
Nr. of Employees
small (1-50)
Biotech Développement Conseils
Neuilly-sur-seine, Ile-de-France, France, Europe
Services
Market assessment, technology survey, due diligence, partner identification and strategic recommendations to increase asset value prior to commercialization.
Identification of licensing and partnership opportunities, negotiation and deal structuring through to closure.
Support for fundraising, M&A, trade sales and valuation to capture and monetize company value.
IP strategy, freedom-to-operate analysis, contract drafting and IP-related due diligence for international transactions.
Market assessment, technology survey, due diligence, partner identification and strategic recommendations to increase asset value prior to commercialization.
Identification of licensing and partnership opportunities, negotiation and deal structuring through to closure.
Support for fundraising, M&A, trade sales and valuation to capture and monetize company value.
IP strategy, freedom-to-operate analysis, contract drafting and IP-related due diligence for international transactions.
Expertise Areas
- Business development and licensing
- Corporate strategy and M&A advisory
- Scouting and due diligence
- Asset and technology valuation
Key Technologies
- Biomarkers and personalized medicine
- In vitro diagnostics
- Vaccines
- Cell and gene therapy
News & Updates
Advisory and fundraising support for a client that achieved a $24 million capital raise from US and Korean investors.
Support in securing a collaboration agreement with a mid-pharma and obtaining term-sheets for fundraising.
Advisory and fundraising support for a client that achieved a $24 million capital raise from US and Korean investors.
Support in securing a collaboration agreement with a mid-pharma and obtaining term-sheets for fundraising.